Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/06/2003US20030027818 Treatment of cancers
02/06/2003US20030027817 Combination therapy for treatment of bipolar disorders
02/06/2003US20030027816 Oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate salt or solvate; useful for treatment of psychotic patients
02/06/2003US20030027815 10-(4-cyclohexylbenzoyl)-10,11-dihydro-5H-pyrrolo(2,1-c)(1,4)b enzodiazepine derivatives, useful for suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including premature labor
02/06/2003US20030027812 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc.
02/06/2003US20030027811 Compositions containing alpha-2-adrenergic agonist components
02/06/2003US20030027808 Imidazoly-5-yl)methyl-2-quinolinone derivatives, together with platinum coordination compound selected from cisplatin or carboplatin; useful as anticarcinogenic agent
02/06/2003US20030027807 Vitronectin receptor antagonists, their preparation and their use
02/06/2003US20030027806 Triptolide analogs for the treatment of autoimmune and inflammatory disorders
02/06/2003US20030027805 Use of 1,4-androstadienedione as a method of increasing levels of the anabolic/androgenic steroid boldenone in humans
02/06/2003US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids
02/06/2003US20030027803 Administering methoxyestradiol and/or its analogues for inhibiting the proliferation of cancerous brain and nervous system cells and
02/06/2003US20030027802 Methods for preventing antipsychotic-induced weight gain
02/06/2003US20030027801 Administering substitued guanidine compounds for therapy of decreased blood flow or nutrient supply to retinal tissue or optic nerve, or retinal ischemia or trauma, or optic nerve injury
02/06/2003US20030027800 LPA receptor agonists and antagonists and methods of use
02/06/2003US20030027799 As anticancer agents
02/06/2003US20030027797 For therapy of metabolic disorders related to insulin resistance or hyperglycemia
02/06/2003US20030027796 Administering to a subject an effective amount of a therapeutic compound containing phosphonate group and carboxylate group such that modulation of amyloid deposition occus
02/06/2003US20030027794 N-heterocyclic derivatives as NOS inhibitors
02/06/2003US20030027793 Transdermal treatment of parkinson's disease
02/06/2003US20030027791 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
02/06/2003US20030027790 Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
02/06/2003US20030027789 Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
02/06/2003US20030027786 Lipase inhibiting composition
02/06/2003US20030027785 Administering to a subject a purinergic receptor agonist in an amount therapeutically effective to alter the amount or formulation of synovial fluids
02/06/2003US20030027783 Introducing into the cell an RNA comprising a double stranded structure having nucleotide sequence which is substantially identical to part of target gene and which is derived from an endogenous template; verifying inhibition of expression
02/06/2003US20030027774 For diagnosis and therapy of tuberculosis
02/06/2003US20030027773 Protein-polycation conjugates
02/06/2003US20030027772 Composition containing at least one inhibitor of the enzyme 3-beta-HSD
02/06/2003US20030027759 Method of using PON-1 to decrease atheroma formation
02/06/2003US20030027746 Useful in the development of human therapeutics and diagnostic formulations
02/06/2003US20030027743 Tripeptidylpeptidase inhibitors
02/06/2003US20030027337 Sequence-specific DNA recombination in eukaryotic cells
02/06/2003US20030027304 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
02/06/2003US20030027302 Ligand for use in radioimmunotherapy
02/06/2003US20030027284 Tumor necrosis factor-gamma
02/06/2003US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
02/06/2003US20030027239 Creatinine biosensor
02/06/2003US20030027233 Cell separation compositions and methods
02/06/2003US20030027230 Detection of antiproliferative agents for treatment of ovarian cancer; obtain cells, incubate with modulator, monitor cells for reduction in cancer activity, reduction in cancer activity indicates antiproliferative agents
02/06/2003US20030027211 Fetuin-MGP-mineral complex in serum
02/06/2003US20030027198 Nucleotide sequences coding polypeptide for use in the treatment of tumors
02/06/2003US20030027188 SLC7s as modifiers of the p53 pathway and methods of use
02/06/2003US20030027177 Human DNA mismatch repair proteins
02/06/2003US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
02/06/2003US20030027130 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of viral diseases
02/06/2003US20030026862 (+)-Cycloolivil as antioxidant obtained from a new natural source namely stereospermum personatum
02/06/2003US20030026860 Administering calcium compoound and fat blend
02/06/2003US20030026854 Plant drug for treatment of liver disease
02/06/2003US20030026853 Method and composition for treatment of inflammatory and inflammation-related disorders
02/06/2003US20030026851 Mixture of plant extract and oxidation resistance compound
02/06/2003US20030026849 Vasodilation; cardiovascular disorders; antiischemic agents
02/06/2003US20030026840 Immobilized into polyoxyethylene glycol
02/06/2003US20030026839 Melt-extrusion multiparticulates
02/06/2003US20030026837 Effervescent solid composition of matter
02/06/2003US20030026834 Analgesics
02/06/2003US20030026830 Silicone transdermal patch
02/06/2003US20030026829 Analgesic patch
02/06/2003US20030026825 Method of deterring woodpeckers
02/06/2003US20030026823 Environmentally safe insect repellent composition
02/06/2003US20030026822 Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs
02/06/2003US20030026820 Use of a compositon containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin
02/06/2003US20030026819 Protective coating for skin
02/06/2003US20030026818 Composition for external application
02/06/2003US20030026811 Health food and preparation having an anti-obesity effect
02/06/2003US20030026802 Interference with binding chemokines
02/06/2003US20030026799 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
02/06/2003US20030026796 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
02/06/2003US20030026784 Cardiovascular disorders; genetic engineered mouse
02/06/2003US20030026782 Viricides
02/06/2003US20030026774 Mixture of quaternary ammonium compound and polyalcohol
02/06/2003US20030026766 Administering by inhalation
02/06/2003CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs)
02/06/2003CA2493596A1 Novel targeted delivery system for bioactive agents
02/06/2003CA2457954A1 Composition comprising cysteamine for specific use in poultry raising and egg production
02/06/2003CA2455681A1 An inducer of apoptosis
02/06/2003CA2454903A1 Substituted piperazines as modulators of the melanocortin receptor
02/06/2003CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a
02/06/2003CA2454791A1 Antisense modulation of c-reactive protein expression
02/06/2003CA2454774A1 Polymorph salt of a pyridazinone derivative for the treatment of arrythmia
02/06/2003CA2454702A1 Novel compounds
02/06/2003CA2454681A1 Medicament inhibiting sodium/calcium exchange system
02/06/2003CA2454656A1 Methods and compositions for treating fungal infections
02/06/2003CA2454564A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor
02/06/2003CA2454342A1 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
02/06/2003CA2454183A1 Methods and compositions for rnai mediated inhibition of gene expression in mammals
02/06/2003CA2454150A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
02/06/2003CA2453919A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
02/06/2003CA2453894A1 Antisense modulation of hormone-sensitive lipase expression
02/06/2003CA2453587A1 Benzofuranes and their use in the treatment of atrial fibrillation
02/06/2003CA2453019A1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
02/06/2003CA2452328A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/06/2003CA2449462A1 Methods for promotion of hair growth comprising topical application of prostaglandin analogues
02/06/2003CA2448722A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
02/06/2003CA2419089A1 Composition comprises sustained-release fine particles for quick-disintegrating tablets in the buccal cavity and manufacturing method thereof
02/06/2003CA2399583A1 Novel solvate and crystalline forms of lercanidipine hydrochloride
02/06/2003CA2380202A1 Novel crude and crystalline forms of lercanidipine hydrochloride
02/05/2003EP1282084A2 Method for preparing pyrimidone derivatives with antifungal activity
1 ... 5570 5571 5572 5573 5574 5575 5576 5577 5578 5579 5580 5581 5582 5583 5584 5585 5586 5587 5588 5589 5590 ... 7860